When a newborn has polycythemia, it means they have too many red blood cells. A doctor typically diagnoses polycythemia using a hematocrit test. Polycythemia can lead to thickening of the blood and ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

The HemataStat II ™ from EKF Diagnostics is a microhematocrit centrifuge that delivers quantitative hematocrit readings for up to six blood samples in just a 60-second spin. Hematocrit is the volume ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

Increases in the proportion of red blood cells mediates the reduction in renal risks associated with SGLT2 inhibitor therapy in patients with type 2 diabetes and cardiovascular disease, a study found.

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...